VIR Live signaler | Maksimer profitt med Getagraph.com

KJøP 114264 min ago

@ $9.72

Utstedt: 14 feb 2024 @ 19:10

Avkastning: 6.89%

Forrige signal: feb 14 - 15:30

Forrige signal: Selg

Avkastning: 6.58 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	1.66M
Gjennomsnittsvolum	1.04M
Markedsverdi	1.41B
EPS	$0 ( 2024-05-02 )
Neste inntjeningsdato	( $-1.050 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.26
ATR14	$0.0160 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	De Backer Marianne	Sell	72 995	Common Stock
2024-04-01	Hanly Ann M.	Sell	2 711	Common Stock
2024-03-27	Lee Sung	Sell	6 008	Common Stock
2024-02-22	Hanly Ann M.	Buy	32 500	Common Stock
2024-02-22	Hanly Ann M.	Sell	12 296	Common Stock

INSIDER POWER
-10.23
Last 98 transactions
Buy: 8 177 990 \| Sell: 9 772 896

Volum Korrelasjon

Lang: 0.28 (neutral)

Kort: -0.96 (very strong negative)

Signal:(37.504) Neutral

Vir Biotechnology Inc Korrelasjon

10 Mest positive korrelasjoner
MMAC	0.954
BOCH	0.943
NETE	0.913
TERN	0.867
SHSP	0.859
RAVN	0.843
AMRB	0.843
PTPI	0.836
USLB	0.827
ATER	0.826

10 Mest negative korrelasjoner
PAIC	-0.934
RMRM	-0.927
SVOK	-0.922
SVAC	-0.888
ISNS	-0.888
APOP	-0.887
FEYE	-0.874
GAINL	-0.872
SPRT	-0.837
TDAC	-0.828

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Vir Biotechnology Inc Korrelasjon - Valuta/Råvare

-0.33
( neutral )

-0.63
( weak negative )

0.00
( neutral )

-0.24
( neutral )

0.53
( weak )

-0.49
( neutral )

Vir Biotechnology Inc Økonomi

Annual	2023
Omsetning:	$86.18M
Bruttogevinst:	$63.96M (74.22 %)
EPS:	$-4.59

FY	2023
Omsetning:	$86.18M
Bruttogevinst:	$63.96M (74.22 %)
EPS:	$-4.59

FY	2022
Omsetning:	$1.58B
Bruttogevinst:	$1.43B (90.74 %)
EPS:	$3.89

FY	2021
Omsetning:	$1.10B
Bruttogevinst:	$1.03B (93.99 %)
EPS:	$4.44

Financial Reports:

No articles found.

Vir Biotechnology Inc

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.